Journal: Cell Reports Medicine

Article Title: Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors

doi: 10.1016/j.xcrm.2023.101374

Figure Lengend Snippet:

Article Snippet: Supernatants were collected and tested with ELISA kit (E-EL-H2518, Elabscience).

Techniques: Recombinant, Derivative Assay, Microarray, Enzyme-linked Immunosorbent Assay, Lysis, Blocking Assay, Staining, Transfection, Marker, Flow Cytometry, shRNA, Plasmid Preparation, Negative Control, Silver Staining, Bicinchoninic Acid Protein Assay, Selection, Extraction, Labeling, RNA Expression, Cell Culture, Software

Journal: Biomedicines

Article Title: Potential Role of Circulating PD-L1 + Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients

doi: 10.3390/biomedicines12050958

Figure Lengend Snippet: Concentration of plasma-soluble immunomodulatory factors in NSCLC patients based on anti-PD-(L)1 response. ( A ) IL-17, ( B ) IFN-γ, ( C ) IL-10, ( D ) sIL-6R, and ( E ) IL-6 concentrations (pg/mL) in plasma from PD, SD, and R patients measured at baseline and after 10–12 weeks of treatment. p -values are shown in graphs (*) p < 0.05; (**) p < 0.01; n.s. is not significant. The Kruskal–Wallis test with Dunn’s correction was used to compare baseline concentrations between studied groups, whereas the Wilcoxon test was used to compare baseline and 10–12 week time points for each soluble factor.

Article Snippet: The concentrations of sPD-L1 (Invitrogen, Carlsbad, CA, USA), IL-17A (Peprotech, London, UK), IL-6, IL-10 (Immunotools), IFN-γ (Mabtech, Nacka Strand, Sweden), and sIL-6R (BD Biosciences, San Jose, CA, USA), were measured in the plasma of NSCLC patients treated with PD-(L)1 at baseline and upon 10–12 weeks of follow-up (coinciding with the timing of the first radiological evaluation).

Techniques: Concentration Assay